Monoolein-based nanoparticles containing indinavir: a taste-masked drug delivery system

Area of Science:

• Nanotechnology
• Pharmaceutical Sciences
• Pediatric Medicine

Background:

• Pediatric adherence to antiretroviral therapy (ART) is challenging due to inadequate dosage forms.
• Existing treatments often lack child-friendly formulations, hindering effective HIV management in children.

Purpose of the Study:

• To develop a novel, child-friendly, taste-masked, solvent-free liquid formulation for pediatric HIV treatment.
• To create monoolein-based nanoparticles encapsulating indinavir for improved drug delivery in pediatric patients.

Main Methods:

• Development of monoolein-based nanoparticles containing indinavir (0.1%).
• Comprehensive characterization including particle size, zeta potential, pH, drug content, stability, in vitro drug release, biocompatibility, toxicity, and taste-masking.
• Analysis using small angle X-ray scattering and electron microscopy.

Main Results:

• Nanosized particles (155 nm) with a narrow size distribution (PDI 0.16) and negative zeta potential (-31.3 mV) were achieved.
• High drug incorporation efficiency (96%) and stability for 30 days were observed.
• Sustained drug release, non-irritant properties, and effective taste-masking of indinavir were confirmed.

Conclusions:

• Monoolein-based nanoparticles offer a promising strategy for pediatric antiretroviral treatment.
• This formulation has the potential to reduce dosing frequency and enhance adherence in pediatric HIV patients.